Follow us on Twitter
twitter icon@FreshPatents

Leukemia patents

Bulk PDF Downloads
      

This page is updated frequently with new Leukemia-related patent applications.




 Compositions and methods for the treatment of acute myeloid leukemias and myelodysplastic syndromes patent thumbnailCompositions and methods for the treatment of acute myeloid leukemias and myelodysplastic syndromes
Provided are compositions and methods for the treatment of hematological conditions, in particular cd99+ acute myelogenous leukemias (aml) and myelodysplastic syndromes (mds), which comprise one or more antibody that (a) binds to the extracellular domain of cd99, (b) ligates aml and/or mds cell-surface expressed cd99, (c) promotes the capping/clustering/aggregation aml and/or mds cell-surface expressed cd99, and (d) induces apoptosis in and consequent cytotoxicity of antibody-ligated cd99+ aml and/or mds cells. Disclosed methods include methods for identifying aml and mds patients that are susceptible to treatment with an anti-cd99 antibody by detecting the elevated expression of cd99 in a tissue sample or cell from an aml or mds patient and for treating an aml and/or mds patient exhibiting elevated cd99 gene and or cell-surface protein expression by administering a composition comprising an anti-cd99 antibody, either alone or in combination with one or more additional component such as a mobilizing agent, a transmigration blocking agent, and an aml and/or mds chemotherapeutic agent, such as daunorubicin, idarubicin, cytarabine, 5-azacytidine, and decitabine..
Memorial Sloan-kettering Cancer Center


 Compounds from anisomeles heyneana patent thumbnailCompounds from anisomeles heyneana
The present invention describes use of compounds of formula 1 or 2 or their compositions for the treatment of leukemia and use of compound of formula 1 or its composition for treatment of infections caused due to m. Tuberculosis.
Council Of Scientific & Industrial Research


 Pyrrolo pyrimidine derivative patent thumbnailPyrrolo pyrimidine derivative
A compound represented by the general formula (1) has a pyridone ring structure introduced into a pyrrolo pyrimidine skeleton, so that the compound has a strong axl inhibitory activity. Consequently, the compound can be used as a therapeutic agent for axl-related diseases including cancers such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glioma, kidney diseases, immune system diseases, and circulatory system diseases..
Ono Pharmaceutical Co., Ltd.


 Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7) patent thumbnailPolycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
The present invention provides novel compounds of formula (i), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, lymphoma, melanoma, multiple myeloma, breast cancer, ewing's sarcoma, osteosarcoma, brain cancer, neuroblastoma, lung cancer), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject.
Dana-farber Cancer Institute, Inc.


 Heteromaromatic compounds useful for the treatment of prolferative diseases patent thumbnailHeteromaromatic compounds useful for the treatment of prolferative diseases
The present invention provides novel compounds of formula (i) and formula (ii), and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject.
Syros Pharmaceuticals, Inc.


 Heteroaromatic compounds useful for the treatment of prolferative diseases patent thumbnailHeteroaromatic compounds useful for the treatment of prolferative diseases
The present invention provides novel compounds of formula (i), and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject.
Dana-farber Cancer Institute, Inc.


 Securinine and norsecurinine analogue compounds for the treatment of myeloid disorders patent thumbnailSecurinine and norsecurinine analogue compounds for the treatment of myeloid disorders
The present application relates to securinine or norsecurinine analogues that, when administered to immature myeloid cells, promote differentiation of these cells to mature cells that do not readily proliferate. Therefore, the agents are useful in the treatment of myeloid disorders including myeloproliferative disorders, acute myeloid leukemia, and autoimmune diseases.
Case Western Reserve University


 Kdm1a inhibitors for the treatment of disease patent thumbnailKdm1a inhibitors for the treatment of disease
Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of kdmia, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia..
Imago Biosciences Inc.


 Use of water soluble platinum complex in preparing drugs for prevention and treatment of cancers patent thumbnailUse of water soluble platinum complex in preparing drugs for prevention and treatment of cancers
Disclosed in the present invention is the use of a water soluble platinum complex in preparing drugs for the prevention and treatment of tumors, said platinum complex being shown as formula (i). Experiments have demonstrated that the present water soluble platinum complex alone or in combination with other chemotherapeutics is able to treat cancer in mammals, and in particular, humans, said cancers including lung cancer, colon cancer, head and neck cancer, prostate cancer, breast cancer, ovarian cancer, cervical cancer, leukemia, lymphoid cancer, skin cancer, pancreatic cancer, liver cancer, bladder cancer, esophageal cancer, gastric cancer, male genital cancer or bone cancer..
Gudui Biopharma Technology Inc.


 Monitoring health and disease status using clonotype profiles patent thumbnailMonitoring health and disease status using clonotype profiles
There is a need for improved methods for determining the diagnosis and prognosis of patients with conditions, including autoimmune disease and cancer, especially lymphoid neoplasms, such as lymphomas and leukemias. Provided herein are methods for using dna sequencing to identify personalized, or patient-specific biomarkers in patients with lymphoid neoplasms, autoimmune disease and other conditions.
Adaptive Biotechnologies Corp.


Methods of diagnosing and treating b cell acute lymphoblastic leukemia


Methods for the diagnosis and treatment of b cell acute lymphoblastic leukemia (b-all), based in part on the detection and/or inhibition of focal adhesion kinase (fak), e.g., phosphorylated fak (pfak).. .
Tufts Medical Center


Combination therapy with anti-cd74 and anti-cd20 antibodies provides enhanced toxicity to b-cell diseases


Disclosed are compositions and methods comprising combinations of anti-cd74 and anti-cd20 antibodies or antigen-binding fragments thereof. The antibody combination may also be used with a therapeutic agent that is attached to antibody or fragment thereof or separately administered.
Ibc Pharmaceuticals, Inc.


Methods of treating acute myeloid leukemia with a flt3 mutation


There is provided a method of treating acute myeloid leukemia (aml). The method includes the step of administering to a patient having aml with a fms-like tyrosine kinase 3 (flt3)-mutation a therapeutically effective amount of a cxcr4-antagonistic peptide..
Biolinerx Ltd.


Method for treating acute myeloid leukemia


The present invention relates to the use of bi 6727 or a salt thereof or the hydrate thereof for treating patients suffering from acute myeloid leukemia (aml) comprising the administration of a high dose of bi 6727 according to a specific dosage schedule, optionally in combination with cytarabine.. .
Boehringer Ingelheim International Gmbh


Leukemia stem cell targeting ligands and methods of use


The present invention is directed to c-type lectin-like molecule-1 (cll1) specific ligand peptides, comprising the amino acid motif lr(s/t), and methods of their use, e.g., for imaging detection for diagnosis of leukemia and the presence of leukemic stem cells (lscs) and targeted therapy against leukemia mediated at least in part by cll1-expressing lscs.. .
The Regents Of The University Of California


Kdm1a inhibitors for the treatment of disease


Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of kdm1a, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia..
Imago Biosciences, Inc.


High surface-area lyophilized compositions comprising arsenic for oral administration in patients


The present invention relates to treating malignancies such as tumors or cancers by orally administering lyophilized compositions comprising arsenic to a subject in such need. Malignancies include various hematological malignancies, such as acute myeloid leukemia (aml) including acute promyelocytic leukemia (apl), myelodysplastic syndrome (mds), multiple myeloma (mm) and lymphomas and solid tumors including glioblastoma multiforme and breast cancer.
Orsenix Bv


An anti-leukemic agent useful for inducing differentiation in myeloid leukemia cells


The present invention provides the compound ormeloxifene [3,4-trans-2,2-dimethyl-3-phenyl-4-p-(beta-pyrrolidinoethoxy)phenyl-7-methoxy chroman] as useful in inducing differentiation in wide range of myeloid leukemias including acute promyelocytic leukemia, acute myeloid leukemia and chronic myeloid leukemia where block in differentiation is common feature. Ormeloxifene induced differentiation that is marked by increase in differentiation marker proteins like c/ebpα and surface proteins such as cd11b and granulocyte colony stimulating factor receptor (gcsfr).
Council Of Scienticfic & Industrial Research


Prognostic methods, compositions and kits for prediction of acute lymphoblastic leukemia (all) relapse


The present invention relates to prognostic methods and kits for the assessment and monitoring of relapse-free or disease-free survival of all patients. The detection is based on the use of detecting nucleic acids, specific for determination of the expression of at least one of mir-151-5p and mir-451 in a test sample.
Mor Research Applications Ltd.


Order a batch download of a huge number of patent PDFs. Bulk PDF Downloads This is a premium service.

Anti-cd38 antibodies for treatment of acute myeloid leukemia


The present invention relates to methods of treatment of acute myeloid leukemia with anti-cd38 antibodies.. .
Janssen Biotech, Inc.


Substituted pyrimidine bmi-1 inhibitors


Amine substituted pyrimidine compounds and forms thereof that inhibit the function and reduce the level of b-cell specific moloney murine leukemia virus integration site 1 (bmi-1) protein and methods for their use to inhibit bmi-1 function and reduce the level of bmi-1 to treat a cancer mediated by bmi-1 are described herein.. .
Ptc Therapeutics, Inc.


Substituted indole mcl-1 inhibitors


The present application, among other things, provides compounds that are capable of inhibiting the activity of anti-apoptotic bcl-2 family proteins, for example, myeloid cell leukemia-1 (mcl-1) protein. The present invention also provides pharmaceutical compositions as well as methods for using provided compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of mcl-1 protein.
Vanderbilt University


Anti-human cd52 immunoglobulins


The present invention relates to humanized immunoglobulins, mouse monoclonal antibodies and chimeric antibodies that have binding specificity for human cd52. The present invention further relates to a humanized immunoglobulin light chain and a humanized immunoglobulin heavy chain.
Genzyme Corporation


Wt1 mutations for prognosis of myeloproliferative disorders


The invention provides methods for determining the prognosis of a patient diagnosed with a leukemia, including b-cell chronic lymphocytic leukemia, by measuring mutations of the wt1 gene in a biological sample. The invention also relates to the diagnosis of leukemia, including b-cell chronic lymphocytic leukemia..
Quest Diagnostics Investments Incorporated


Methods of manipulating phagocytosis mediated by cd47


Methods are provided to manipulate phagocytosis of cancer cells, including e.g. Leukemias, solid tumors including carcinomas, etc..
The Board Of Trustees Of The Leland Stanford Junior University


Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias


Methods for assessing a pathological condition in a subject include measuring one or more markers where a difference is indicative of acute lymphoblastic leukemia (all) or a predisposition to all, uses and compositions are disclosed.. .
The Ohio State University Research Foundation


Bispecific cd33 and cd3 binding proteins


Described herein are binding proteins that specifically bind to human cd33, and in particular to bispecific binding proteins that specifically bind to human cd33 and human cd3. Also described herein are bispecific tandem diabodies that bind to cd33 and cd33, and their uses for immunotherapy of cd33+ cancers, diseases and conditions such as acute myeloid leukemia (aml)..
Amphivena Therapeutics, Inc.


Methods and compositions for treatment of retinoid-responsive conditions


Methods and composition for treating a retinoid-responsive condition in a subject are provided according to embodiments of the present invention which include administering a therapeutically effective amount of a substance selected from the group consisting of: neutrophil gelatinase-associated lipocalin (ngal), an ngal analog, an ngal stimulator and an analog of an ngal stimulator, to a subject having a retinoid-responsive condition. Retinoid-responsive conditions illustratively include acne, rosacea, psoriasis, promyelocytic leukemia and neuroblastoma..
The Penn State Research Foundation


Histone demethylase inhibitors


The present invention relates generally to compositions and methods for treating cancer and neoplastic diseases. Provided herein are substituted imidazole-pyridine derivative compounds and pharmaceutical compositions comprising said compounds.
Celgene Quanticel Research, Inc.


Triazolone compounds and uses thereof


The invention disclosed herein is directed to compounds of formula (1a) and (1b) and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocyticδ leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of formula (1a) or (1b), or a pharmaceutically acceptable salt thereof.
Inception 2, Inc.


Styryl quinazoline derivatives as pharmaceutically active agents


The present invention relates to styryl quinazoline derivatives of the general formula (i) and pharmaceutically acceptable solvates, hydrates, salts, regioisomeric and polymorphic forms thereof as well as pharmaceutical compositions containing at least one of the described compounds as pharmaceutically active agent. The compounds have been identified as new drug candidates for the prevention and/or treatment of diseases related to disfunction(s) of hematopoiesis and cancer or any other form of neo- or hyperplasias related to fms-like tyrosine kinase 3 (flt3) containing internal tandem duplications (itd), especially in the case of myeloid leukemia.
Vichem Chemie KutatÓ Kft.


Molecular combinations for cancer or other disease treatment


A method and medicine for treating leukemia or other cancer or disease condition including administering periodic doses of a combination of one or more of emodin, rhein or rhapontin with one or more of aucubin, digoxin or beta-sitosterol, and/or one or more of carvacrol, vanillic acid or sitosterol.. .

Molecular combinations for cancer or other disease treatment


A method and medicine for treating leukemia or other cancer or disease condition including administering periodic doses of a combination of one or more of emodin, rhein or rhapontin with one or more of aucubin, digoxin or beta-sitosterol, and/or one or more of carvacrol, vanillic acid or sitosterol.. .

Method of treating mixed lineage leukemia gene-rearranged acute lymphoblastic leukemias


The present invention relates to a method of treating a warm-blooded animal, especially a human, having mixed lineage leukemia (mll rearranged all) comprising administering to said animal a therapeutically effective amount of a staurosporine derivative, especially pkc412 or a pharmaceutically acceptable salt thereof, alone or in combination with further therapeutic measures, for example, those defined herein; to the use of a staurosporine derivative for the preparation of a medicament for the treatment of mll rearranged all; and to a commercial package comprising a staurosporine derivative together with instructions for its use in the treatment of mll rearranged all.. .

Methods of manipulating phagocytosis mediated by cd47


Methods are provided to manipulate phagocytosis of cancer cells, including e.g. Leukemias, solid tumors including carcinomas, etc..

Methods of manipulating phagocytosis mediated by cd47


Methods are provided to manipulate phagocytosis of cancer cells, including e.g. Leukemias, solid tumors including carcinomas, etc..

2-substituted imidazo[4,5-d]phenanthroline derivatives and their use in the treatment of cancer


The present invention provides 2-substituted imidazo[4,5-d]phenanthroline compounds, which are capable of inhibiting proliferation of one or more renal cancer cells, pancreatic cancer cells, prostate cancer cells, colon cancer cells, leukemia cells, brain cancer/tumour cells or non-small cell lung cancer cells.. .

Treatment of leukemia with artemisinin derivatives and combinations with other antineoplastic agents


Methods of treating cancer, such as leukemia, via administration of therapeutically effective amounts of artemisinins and second agents are detailed herein. The artemisinins include artesunate, dihydroartemisinin, artemether, arteether, artelinate, and art-838.

Compositions, methods and kits for treating cancer


Compositions, kits and methods for treating leukemia in a subject (e.g., human) include a first anti-cancer drug consisting of: Δ12-prostaglandin j3 or a derivative thereof, or a prostaglandin d receptor (dp) agonist. The compositions may further include a second anti-cancer drug.

Order a batch download of a huge number of patent PDFs. Bulk PDF Downloads This is a premium service.

Pim kinase inhibitor combinations


The present invention relates to a pim kinase inhibitor compound that can be used alone or in a pharmaceutical combination. One such combination comprises (a) a jak inhibitor compound, (b) a pim kinase inhibitor compound, and optionally, at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the treatment of a myeloid neoplasm or leukemia; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of myeloid neoplasm or leukemia; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a mammal, especially a human..

Quinoline derivative


A compound represented by general formula (i) has a strong axl inhibitory activity by introducing a distinctive bicyclic structure in which a saturated carbon ring is fused to a pyridone ring, and can be a therapeutic agent for axl-related diseases, for example, cancer such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glioma, kidney diseases, immune system diseases, and circulatory system diseases.. .
Ono Pharmaceutical Co., Ltd.


Combination methods for treating cancers


Or a pharmaceutically acceptable salt thereof; in combination with a vinca-alkaloid, or a pharmaceutically acceptable salt thereof. The subject may be very high risk or high risk for the cancer and may not respond to either agent administered as a sole therapy.

Azacyclic constrained analogs of fty720


Small molecules comprised of azacyclic constrained analogs of fty720 are provided. Formulations and medicaments are also provided that are directed to the treatment of disease, such as, for example, leukemia, and other diseases.
The Regents Of The University Of California


Pharmaceutical formulation containing thienotriazolodiazepine compounds


A method of treating lymphoblastic leukemia, acute myeloid leukemia, bcr-abl positive acute lymphoblastic leukemia or cd34 positive acute myeloid leukemia comprising the step of administering to a patient a pharmaceutically acceptable amount of a composition comprising a thienotriazolodiazepine compound according to formula (1) as a solid dispersion wherein x is a halogen, r1 is c1-c4 alkyl, r2 is c1-c4 alkyl, a is an integer of 1-4, r3 is c1-c4 alkyl, c1-c4 hydroxyalkyl, c1-c4 alkoxy, phenyl optionally having substituent(s), or heteroaryl optionally having substituent(s), a pharmaceutically acceptable salt thereof or a hydrate thereof; and a pharmaceutically acceptable polymer. In one embodiment, the pharmaceutically acceptable polymer is hpmcas..
Oncoethix Gmbh


Use of an h4 agonist molecule to treat acute leukemia


The present invention relates to the use of new chemical substances, the levogyre and dextrogyre enantiomers of (amino-7 triethoxy-4, 5, 6 oxo-1 dihydro-1, 3 isobenzofurannyl-3)-1 methoxy-8 methyl-2methylenedioxy-6, 7 tetrahydro-, 2, 3, 4 isoquinoleine or tritoqualine, to treat acute myeloid or lymphoid leukemia, with the exception of type b leukemia.. .
Chrysalis Pharma


A new fusion protein to target and treat acute myloid leukemia cells


A polypeptide which binds to the surface of aml blast cells and is internalised upon binding to the aml blast cells.. .
Rheinisch-westfaelische Technische Hochschule Aachen


Method for screening drugs for treating/preventing myelodysplastic syndrome, etc.


(b) a step of selecting the test substance as a candidate for a therapeutic or prophylactic drug for acute myeloid leukemia or myelodysplastic syndrome and the like when the colony number in the presence of the test substance increases from the colony number in the absence of the test substance.. .



Leukemia topics:
  • Myelogenous
  • Myelogenous Leukemia
  • Proliferative
  • Autoimmune
  • Stem Cells
  • Breast Cancer
  • Rheumatoid Arthritis
  • Myeloid Leukemia
  • Acute Myelogenous Leukemia
  • Lymphocytic
  • Chronic Lymphocytic Leukemia
  • Lymphocytic Leukemia
  • Epigenetic
  • Multiple Myeloma
  • Polyphenol


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Leukemia for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Leukemia with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.9366

    5224

    2 - 1 - 102